Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 184,860 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NOT program Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenomics of Thiazolidinediones

NCT01135394
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Pioglitazone
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
35 Years to 64 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 28, 2026, 11:21 PM EDT
Terminated Phase 3 Interventional

Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)

NCT02410356
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
TV-1106, dGH
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Artesia, California • Fountain Valley, California • Lakewood, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 28, 2026, 11:21 PM EDT
Terminated Phase 2 Interventional Results available

Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00496756
View directory record Official record
Conditions
Kidney Cancer
Interventions
Sorafenib
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 120 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

NCT06817356
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Mazdutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
25
States / cities
Scottsdale, Arizona • Rogers, Arkansas • Fountain Valley, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 28, 2026, 11:21 PM EDT
Terminated Phase 3 Interventional Results available

CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)

NCT04348656
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent plasma
Biological
Lead sponsor
Hamilton Health Sciences Corporation
Other
Eligibility
16 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD

NCT03051256
View directory record Official record
Conditions
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Interventions
REL-1017, Placebo
Drug
Lead sponsor
Relmada Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Little Rock, Arkansas • Garden Grove, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 28, 2026, 11:21 PM EDT
Not listed No phase listed Observational

Discovering Factors in the Clinical Study Journey of Patients With OCD

NCT05881356
View directory record Official record
Conditions
OCD, Obsessive-Compulsive Disorder
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 28, 2026, 11:21 PM EDT
Withdrawn Phase 2 Interventional

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

NCT04209556
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-06826647 100 mg QD, PF-06826647 300 mg QD, PF-06826647 600 mg QD, Placebo, PF-6826647 400 mg QD
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
24
States / cities
Canoga Park, California • Inglewood, California • Newport Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Not applicable Interventional

Treatment of Disruptive Behaviors in Fragile X Syndrome

NCT03510156
View directory record Official record
Conditions
Fragile X Syndrome, Disruptive Behavior
Interventions
Behavior analytic treatment
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 10 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 2 Interventional

A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis

NCT00001422
View directory record Official record
Conditions
Arthritis, Psoriatic, Psoriasis
Interventions
fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Evaluation of a Q-fever Vaccine, NDBR 105

NCT00584454
View directory record Official record
Conditions
Q Fever
Interventions
Q Fever Vaccine (NDBR 105
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
17 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 28, 2026, 11:21 PM EDT
Withdrawn No phase listed Observational

Sarah Cannon Outcomes Registry

NCT02356822
View directory record Official record
Conditions
Oncology
Interventions
Patient registry
Other
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Not applicable Interventional

ETT Cuff Leak: TV Ratios

NCT02768831
View directory record Official record
Conditions
Surgical Procedures, Operative
Interventions
CPAP, Tidal volume
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 28, 2026, 11:21 PM EDT
Recruiting Phase 4 Interventional

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

NCT07224529
View directory record Official record
Conditions
Meibomian Gland Dysfunction (MGD)
Interventions
Vevye(Cyclosporine 0.1% Ophthalmic Solution)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 28, 2026, 11:21 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transcutaneous Vagus Nerve Stimulation (tVNS) and Stress Regulation During Performance Tasks

NCT07470229
View directory record Official record
Conditions
Stress Response
Interventions
Transcutaneous Vagus Nerve Stimulation (tVNS), Evaluative Stress Task
Device · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 28, 2026, 11:21 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Step Up for STEM and Health Careers

NCT06445751
View directory record Official record
Conditions
Adolescent Behavior
Interventions
Step Up for STEM and Health Careers ("Step Up") game, Educational PowerPoint Presentation on Diversity in STEM Careers
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
13 Years to 19 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Treating Obese and Lean Patients With Sleep Apnea

NCT01578031
View directory record Official record
Conditions
Sleep Apnea, Obesity
Interventions
Positive Airway Pressure During Sleep (ResMed S9 Elite), Usual Care
Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 28, 2026, 11:21 PM EDT
Not listed Not applicable Interventional

Efficacy of a Single Injection of CTM for Post-Operative CMC Arthritis

NCT06171529
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis Thumb Base Joint, Carpometacarpal Osteoarthritis, Thumb
Interventions
CTM, Placebo
Device · Other
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Phase 3 Interventional Results available

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

NCT02251431
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
Interventions
BYDUREON, Placebo
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Not applicable Interventional

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

NCT02113631
View directory record Official record
Conditions
Hepatitis C, Chronic, Cirrhosis
Interventions
Telaprevir, Boceprevir, Peg-IFN, Ribavirin
Drug
Lead sponsor
Louis Stokes VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 28, 2026, 11:21 PM EDT
Terminated Phase 1 Interventional

Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

NCT00101231
View directory record Official record
Conditions
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Blastic Phase Chronic Myelogenous Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia
Interventions
alvocidib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 28, 2026, 11:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibrosis Center

NCT03052231
View directory record Official record
Conditions
Medication Adherence, Cystic Fibrosis
Interventions
caremessage
Device
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
4 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 28, 2026, 11:21 PM EDT
Not listed Not applicable Interventional

Efficacy of a Custom Temporary Foot Orthosis for Plantar Fasciitis Treatment

NCT01882894
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Custom PFO, Faux orthosis
Device · Other
Lead sponsor
University of Puget Sound
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 28, 2026, 11:21 PM EDT
Withdrawn Phase 2 Interventional

Telaglenastat + Talazoparib In Prostate Cancer

NCT04824937
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Telaglenastat, Talazoparib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 11:21 PM EDT